Biomarkers for osteoarthritis: Current position and steps towards further validation

Best Practice and Research: Clinical Rheumatology

Volumn 28, Issue 1, 2014, Pages 61-71

  Hunter, David J ^a   Nevitt, Michael ^b   Losina, Elena ^c,d   Kraus, Virginia ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Osteoarthritis

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PATHWAY; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; HUMAN; KNEE OSTEOARTHRITIS; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; VALIDATION PROCESS;

BIOMARKERS; OSTEOARTHRITIS;

BIOLOGICAL MARKERS; HUMANS; OSTEOARTHRITIS; VALIDATION STUDIES AS TOPIC;

EID: 84901617622     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2014.01.007     Document Type: Review

References (38)

1. Prevalence of disabilities and associated health conditions among adults-United States, 1999. [Erratum appears in MMWR Morb Mortal Wkly Rep 2001 Mar 2;50(8): 149.]. MMWR - Morbid Mortal Week Rep 2001;50: 120-5.
2. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Pub Health 1994;84: 351-8.
3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380: 2197-223.
4. Painful Realities: The economic impact of Arthritis in Australia in 2007. 2007. Access Economics, Arthritis Australia. Ref Type: Report. http://www.arthritisaustralia.com.au/index.php/reports/painful-realities-2007. html.
5. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age of diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken); 2012.
6. Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs; 2011.
7. ZhangW, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthrit Cartil 2010;18: 476-99.
8. Arthritis: The Nation's Most Common Cause of Disability. 2012. Ref Type: Internet Communication.
9. Arthritis prevalence and activity limitations-United States, 1990. MMWR - Morbid Mortal Week Rep 1994;43: 433-8.
10. Hunter DJ, Losina E, Guermazi A, Burstein D, Lassere MN, Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr Drug Targets 2010;11: 536-45.
11. Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. [Review] [87 refs]. Pharmacol Rev 2007;59: 40-53.
12. Altar CA. The Biomarkers Consortium: on the critical path of drug discovery. Clin Pharmacol Therapeut 2008;83: 361-4.
13. FDA. Critical Path Initiative. http://www.fda.gov/oc/initiatives/ criticalpath/. 2009. [17-3-2009. Ref Type: Electronic Citation].
14. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. [Review] [29 refs]. Clin Pharmacol Therapeut 2001;69: 89-95.
15. Richter WS. Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging 2006; 33(Suppl. 1): 6-10.
16. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs [see comment] J Health Econ 2003;22: 151-85.
17. Berndt E, Gottschalk A, Strobeck M. Opportunities for improving the drug development process: results from a survey of industry and FDA. MIT-FDA-Industry White Paper. http://web.mit.edu/cbi/docs/berndt-et-al6-3-05.pdf. 2006. [17-3-2009. Ref Type: Electronic Citation].
18. Bingham III CO, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study [see comment] Arthritis Rheumatism 2006;54: 3494-507.
19. Food and Drug Administration. Guidance for industry. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). http://www.fda.gov/Cber/gdlns/osteo.htm. 1999. [17-3-2009. Ref Type: Electronic Citation].
20. Mazzuca SA, Brandt KD. Is knee radiography useful for studying the efficacy of a disease-modifying osteoarthritis drug in humans?. [Review] [22 refs]. Rheumat Dis Clin N Am 2003;29: 819-30.
21. Mazzuca SA, Brandt KD, Buckwalter KA, Lequesne M. Pitfalls in the accurate measurement of joint space narrowing in semiflexed, anteroposterior radiographic imaging of the knee. Arthritis Rheumat 2004;50: 2508-15.
22. Gossec L, Hawker G, Davis AM, Maillefert JF, Lohmander LS, Altman R, et al. OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. [12 refs]. J Rheumatol 2007;34: 1432-5.
23. Losina E,Walensky RP, Reichmann WM, Holt HL, Gerlovin H, Solomon DH, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011;154: 217-26.
24. Alpert JS. The Vioxx debacle. Am J Med 2005;118: 203-4.
25. Guermazi A, Burstein D, Conaghan P, Eckstein F, Hellio Le Graverand-Gastineau MP, Keen H, et al. Imaging in osteoarthritis. [Review] [183 refs]. Rheumat Dis Clin N Am 2008;34: 645-87.
26. Hunter DJ, Zhang YQ, Tu X, LaValley M, Niu JB, Amin S, et al. Change in joint space width: hyaline articular cartilage loss or alteration in meniscus? Arthritis Rheumat 2006;54: 2488-95.
27. Lassere M. A users guide to measurement in medicine. Osteoarthrit Cartil 2006;14(Suppl. 1): 10-4.
28. Reichmann WM, Maillefert JF, Hunter DJ, Katz JN, Conaghan PG, Losina E. Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review. Osteoarthritis Cartil 2011;19: 550-6.
29. Hunter DJ, Zhang W, Conaghan PG, Hirko K, Menashe L, Reichmann WM, et al. Responsiveness and reliability of MRI in knee osteoarthritis: a meta-analysis of published evidence. Osteoarthritis Cartilage 2011;19: 589-605.
30. Hunter DJ, Zhang W, Conaghan PG, Hirko K, Menashe L, Li L, et al. Systematic review of the concurrent and predictive validity of MRI biomarkers in OA. Osteoarthritis Cartil 2011;19: 557-88.
31. Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacovelli G, Olejarova M, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartil 2008;16: 254-60.
32. Conaghan PG, Hunter DJ, Maillefert JF, Reichmann WM, Losina E. Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartil 2011;19: 606-10.
33. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartil 2006;14: 723-7.
34. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartil 2011;19: 515-42.
35. Lesko LJ, Atkinson Jr AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. [Review] [61 refs]. Annu Rev Pharmacol Toxicol 2001;41: 347-66.
36. Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. [Review] [14 refs]. Toxicology 2008;245: 219-23.
37. Lester G. Clinical research in OA-the NIH Osteoarthritis Initiative. J Musculoskelet Neuronal Interact 2008;8: 313-4.
38. Peterfy CG, Schneider E, Nevitt M. The osteoarthritis initiative: report on the design rationale for the magnetic resonance imaging protocol for the knee. [Review] [40 refs]. Osteoarthritis Cartil 2008;16: 1433-41. and Skin Diseases and Skin Diseases Skin Diseases